EGFR inhibition augments the therapeutic efficacy of the NAT10 inhibitor Remodelin in Colorectal cancer
Our study elucidated the mechanism underlying 5-Fu-induced NAT10 downregulation, revealing that NAT10 inhibition destabilizes ERRFI1 mRNA through ac4C modifications, subsequently resulting in EGFR reactivation. A triple therapy regimen of Remodelin, cetuximab, and 5-Fu showed potential as a treatment strategy for CRC with wild-type KRAS, NRAS and BRAF.
Authors
- Yanxin An
- Gongcai Tao
- Fengyu Cao
- Ming Guo (ORCID: https://orcid.org/0000-0003-4353-5331)
- Dan Song (ORCID: https://orcid.org/0000-0002-8764-7610)
- Yongbin Zheng (ORCID: https://orcid.org/0000-0002-3631-7929)
- Zhongyuan Xia (ORCID: https://orcid.org/0000-0002-5807-9554)
- Xiaobo He (ORCID: https://orcid.org/0000-0002-6114-6834)
- Chenhong Wang (ORCID: https://orcid.org/0000-0003-0336-9279)
- Dan Luo (ORCID: https://orcid.org/0000-0002-7478-232X)
- Lele Liu (ORCID: https://orcid.org/0000-0002-5980-0761)
- Qingchuan Zhao (ORCID: https://orcid.org/0000-0002-2132-7817)
- Mingzhen Ma
Institutions
- Wuhan University (CN)
- National Clinical Research Center for Digestive Diseases (CN)
- Xi'an Medical University (CN)
- Minda Hospital (CN)
- Renmin Hospital of Wuhan University (CN)
- Xijing Hospital (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1186/s13046-025-03277-y
- Citations
- 6
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 4.84
Funders
- National Natural Science Foundation of China